Skip to content

Does local application of betamethasonvalerate 0,1% cream twice a day reduce the complaints of chronic chillblains?

Betamethason and complaints of chronic chilblains.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22759
Enrollment
60
Registered
2010-01-19
Start date
2010-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic perniones Chilblains

Interventions

Local application on the affected skin parts of betamethasonvalerate 0,1% cream twice a day for a period of six weeks.

Sponsors

Radboud University Nijmegen department Womens Studies Medicine (head: Prof. Dr. A.L.M. Lagro Janssen).
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Population: Patients with complaints of chronic chillblains referred to us in the winters of 2009-2010, 2010-2011 and 2011-2012 by GPs in the north west of the Netherlands. And subjects who attended our 2003-2004 study on the effect of vitamin D3. Inclusion criteria: 1. Age: As of 18 years old; 2. Able to follow instructions and complete a diary; 3. At least 3 weeks of complaints at inclusion: Itching or painful lesions at fingers, toes or other places at the feet or te thighs (the Kibes). The complaints started in the period december to february. There may be swelling and there may be ulceration but these criteria are not obligate.

Exclusion criteria

Exclusion criteria: 1. A patient history of inflammatory disease; 2. Pregnancy; 3. Breast feeding; 4. Actual use of a calcium entry blocker; 5. Use of corticosteroid containing cream or ointment in the past four weeks; 6. Ulcera on the places to be treated.

Design outcomes

Primary

MeasureTime frame
We consider the intervention to be effective when a reduction of complaints or disability occurs of 10mm, as recorded by the subjects on a 100mm Visual analogue scale.

Secondary

MeasureTime frame
Secundary we register side effects: skin irritation an signs of skin atrophy.

Contacts

Public ContactI.H. Souwer

Middelie 91

i.souwer@wxs.nl+31 (0)299 621350

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)